| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_870c6e68c09f6b820fc9b7fefe1a56fc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate |
2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6df331f362682ec4dc84855478b87348
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_885a8a8cac26e695c8128bc2704c3cfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d20bd99a1e406fb80865a78d38a8f14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f7b79eb63745fc1765ea8ab6d7b02b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fd0c726a178331b79d7fdba0f180003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7cccbf8f0cb87d9803db8972bbfc7c0 |
| publicationDate |
2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020354682-A1 |
| titleOfInvention |
Methods for differentiating mesenchymal stem cells |
| abstract |
The application discloses a method for obtaining MSC-derived cells with improved transplantation properties from MSC, the method comprising a cell size reduction step, wherein said cell size reduction step is characterized by contacting MSC or MSC-derived cells in vitro or ex vivo with heparin or a derivative or analogue thereof at a concentration of at least 0.01 IU/ml. The application further provides a method for obtaining mesenchymal stem cell-derived cells from mesenchymal stem cells (MSC) comprising contacting MSC in vitro or ex vivo with FGF-2, TGFβ and at least 0.01 IU/ml heparin or a derivative or analogue thereof. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113648417-A |
| priorityDate |
2017-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |